Skip to content
thestock.space

Colinz Laboratories (BSE: COLINZ) had a P/E of 6.2× on 6 Nov 2026, below the industry P/E of 28.7×, and the shares are 22% below their 52-week high. Sales fell 5.0% a year over 3 years while net profit grew 4.4%; its ROCE of 7.2% is the lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, though net profit is above operating profit, which points to a one-off gain. It carries very little debt. It is a small-cap company with a market cap of ₹17 Cr, ranked 142nd of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 56% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹68.99
Day high
₹68.99
Day low
₹68.99
Prev. close
₹68.99
Volume
100

Health check

2 good · 3 to check
  • ReturnsAhead

    +56.0% over a year, better than 6 of 7 peers.

  • Price tagDistorted

    A one-off gain inflates profit, so P/E isn’t comparable right now.

  • GrowthSlow

    Sales −5.0%, profit +4.4% a year over 3 years.

  • ProfitabilityWeak

    ROCE 7.2% vs peer median 17.9%.

  • Balance sheetSolid

    Practically debt-free, Piotroski 6 of 9.

  • Red flags3 to check

    Return on equity is low at 5.3%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹17 Cr, #142 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2026: sales ₹6 Cr · profit ₹3 Cr
Market cap
₹17 Cr
Small cap
P/E
6.2
Industry 28.7
Price to book
1.73
Peers 4.99
Dividend yield
0.00%
ROE
5.3%
Peers 14.7%
ROCE
7.2%
Peers 17.9%
Debt to equity
0.04
Debt ₹0.39 Cr
EPS (TTM)
₹11.10
OPM (TTM)
5.7%
Net margin 48.1%
Sales growth
−20.8%
Latest quarter vs a year ago
Profit growth
+1914.4%
Latest quarter vs a year ago
Price to sales
2.99
EV/EBITDA 27.2

Strengths and risks

Strengths

  • Practically debt-free.
  • Quarterly profit up 1914.4% on a year ago.

Risks to check

  • Return on equity is low at 5.3%.
  • Quarterly sales down 20.8% on a year ago.
  • Net profit is above operating profit, so a one-off gain is likely flattering earnings.

Derived automatically from reported figures. Not a recommendation.

About Colinz Laboratories

Colinz Laboratories Limited manufactures and trades in pharmaceutical formulations in India. The company offers pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, ointments, injectables, creams, syrups, suppositories, etc.; and specialized products for gynaecology, cardiology, and gastroenterology, etc. Its allopathy products include oncology products, such as imitinib, erlotinib, letrozole, exemestane,…

Headquarters
Mumbai
Employees
62
Sector
Healthcare
ISIN
INE923C01011
Website
colinz.com

Price range

52 weeks

₹36.11₹87.91

Today

₹68.99₹68.99
Avg volume (3M)
1.6K
1-year return
plus 56.0%
From 52-week high
minus 21.5%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
COLINZColinz Laboratories68.990.00%176.21.737.2%5.3%5.7%−5.0%4.4%0.00%plus 56.0%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
1.61.41.41.71.2
1.41.31.31.71.2
0.10.10.10.10.1
8.7%5.7%7.0%5.2%5.0%
0.10.20.10.20.1
00000
00000
––––2.8
0.20.20.10.22.9
25.8%24.7%33.7%20.7%17.2%
0.10.10.10.22.4
0.470.560.33–9.53

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
−5.0%
Profit CAGR 3Y
+4.4%
EPS CAGR 3Y
+3.9%
ROE
5.3%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
7.276.56.1
–minus 1.8%minus 7.1%minus 6.0%
6.56.565.7
0.60.50.50.4
8.8%7.7%7.6%6.6%
0.20.30.30.5
0.1000
0.10.10.10.2
−0–−0–
0.60.70.60.7
23.7%25.2%19.8%25.3%
0.50.50.50.5
–+7.7%+2.0%+3.6%
1.821.931.972.04

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
2.52.52.52.5
5.66.477.5
0.30.60.60.4
1.81.81.72.3
10.211.411.812.8
1.71.61.71.5
0.7111.1
5.775.68.5
2.11.83.51.6
10.211.411.812.8

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
0.41−1.52.5
00−0.20
0.10.20.20.4
0.51.3−1.53
––−0.3–
0.41−1.72.5

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you